Rani Therapeutics Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $91.2M
- Price
- $0.7904
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.67%
- Volume
- 208.1K
About
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Quick stats
Shares outstanding115.4M
Computed float76.6M
Float / shares66.3%
Cash runway (months)28.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001856725
AI Summary
AI-generated1/14
minorbullishregulatory
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
Rani Therapeutics' RaniPill Capsule platform has been accepted into the FDA's Emerging Technology Program, run within CDER to support novel pharmaceutical design and manufacturing approaches.
Participation gives Rani early, direct FDA engagement via pre-submission meetings and potential site visits, covering the platform broadly rather than individual drug products.
Management framed the acceptance as validation of the oral-biologics platform alongside partnerships with Chugai, ProGen, and PegBio, though the milestone carries no immediate financial impact.